Larentine D 5mg/10mg Tablet is a combination pharmaceutical formulation containing Donepezil hydrochloride 5mg and Memantine hydrochloride 10mg, indicated for the treatment of moderate to severe Alzheimer’s disease. Donepezil, a reversible acetylcholinesterase inhibitor, enhances cholinergic function by increasing the concentration of acetylcholine in the brain, thereby improving cognitive function and memory. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, modulates glutamatergic neurotransmission by blocking excessive NMDA receptor activity, which is associated with neurodegenerative processes. The synergistic action of these agents provides a dual mechanism targeting different pathways implicated in Alzheimer’s pathology, potentially offering improved efficacy over monotherapy. Larentine D is administered orally, typically once daily, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include headache, dizziness, gastrointestinal disturbances, and fatigue, which are generally mild to moderate in intensity. Caution is advised in patients with hepatic or renal impairment, and concurrent use with other cholinergic or NMDA-modulating drugs should be monitored closely. Larentine D should be prescribed and used under medical supervision, with regular assessment of cognitive function and overall clinical status to optimize therapeutic outcomes.